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Background: IFN-α contributes extensively to host immune response upon viral infection through antiviral, pro-
apoptotic, antiproliferative and immunomodulatory activities. Although extensively documented in various types of
human cancers and viral infections, controversy exists in the exact mechanism of action of IFN-α in human
immunodeficiency virus type 1 (HIV-1) and human T-lymphotropic virus type 1 (HTLV-1) retroviral infections.
Results: IFN-α displayed strong anti-HIV-1 effects in HIV-1/HTLV-1 co-infected MT-4 cells in vitro, demonstrated by
the dose-dependent inhibition of the HIV-1-induced cytopathic effect (IC50 = 83.5 IU/ml, p < 0.0001) and p24 levels
in cell-free supernatant (IC50 = 1.2 IU/ml, p < 0.0001). In contrast, IFN-α treatment did not affect cell viability or
HTLV-1 viral mRNA levels in HTLV-1 mono-infected cell lines, based on flow cytometry and nCounter analysis,
respectively. However, we were able to confirm the previously described post-transcriptional inhibition of HTLV-1
p19 secretion by IFN-α in cell lines (p = 0.0045), and extend this finding to primary Adult T cell Leukemia patient
samples (p = 0.031). In addition, through microarray and nCounter analysis, we performed the first genome-wide
simultaneous quantification of complete human and retroviral transciptomes, demonstrating significant
transcriptional activation of interferon-stimulated genes without concomitant decrease of HTLV-1 mRNA levels.
Conclusions: Taken together, our results indicate that both the absence of in vitro antiproliferative and
pro-apoptotic activity as well as the modest post-transcriptional antiviral activity of IFN-α against HTLV-1, were not
due to a cell-intrinsic defect in IFN-α signalisation, but rather represents a retrovirus-specific phenomenon,
considering the strong HIV-1 inhibition in co-infected cells.
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The two pathogenic human retroviruses, human im-
munodeficiency virus type 1 (HIV-1) and human T-
lymphotropic virus type 1 (HTLV-1), remain responsible
for significant morbidity and mortality worldwide. At
present, 33 million people are estimated to be infected
with HIV-1 and 10 to 30 million people with HTLV-1
[1,2]. Although both retroviruses share similarities in* Correspondence: johan@bahia.fiocruz.br
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reproduction in any medium, provided the orroutes of transmission and in vivo tropism for CD4+ T
cells, HIV-1 and HTLV-1 significantly differ in patho-
genicity, disease progression and treatment outcome.
Current treatment of HIV-1-infected individuals is based
on highly active antiretroviral therapy (HAART), com-
bining HIV-1 reverse transcriptase, protease, integrase
and/or entry inhibitors [3]. HAART reduces HIV-1
plasma viral loads to undetectable levels in the majority
of patients, hereby slowing down clinical progression to
the acquired immunodeficiency syndrome (AIDS).
HTLV-1, on the other hand, is able to cause adult T cell
leukemia/lymphoma (ATLL), as well as HTLV-1 asso-
ciated myelopathy/tropical spastic paraparesis (HAM/Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ATLL is an aggressive T cell malignancy of mainly CD4
+ CD25+ T cells, affecting up to 6% of HTLV-1-infected
individuals [5]. The diversity of patient symptoms to-
gether with their prognosis has led to the classification
of ATLL into four clinical subtypes: acute, lymphoma,
smouldering and chronic ATLL. Recently, consensus
guidelines have been drafted for ATLL treatment with
first line therapy comprising combination chemotherapy
regimens for lymphoma patients and zidovudine (AZT)
and interferon-α (IFN-α) combination therapy for treat-
ment of acute, smouldering and chronic ATLL patients
[6,7]. Up to 5% of HTLV-1-infected individuals may de-
velop HAM/TSP, a neuro-inflammatory disease charac-
terized by demyelinating lesions and lymphocytic
activation and infiltration into the central nervous sys-
tem [8,9]. Treatment of HAM/TSP patients consists of
mainly symptomatic (antispasmodics) and empirical
strategies such as the use of immunosuppressive drugs
(corticosteroids), IFN-α or vitamin C [10]. However,
consensus guidelines for HAM/TSP treatment are miss-
ing due to the lack of randomized controlled clinical
trials.
Although recent genetic evidence has implicated
IFN/STAT1/FAS signaling in both HAM/TSP and ATL
pathogenesis [11,12], therapeutic options include IFN-α
for both diseases. Initially, IFN-α was implemented in
anti-HTLV-1 treatment because of its effect in HIV-1/
AIDS treatment [13]. IFN-α was one of the first cyto-
kines to be discovered and contributes extensively to
the host immune response upon viral infection. Type I
interferons (IFN-α/β) are expressed and secreted by
various cell types in response to viral infection or rec-
ognition of pathogens [14-16]. IFN-α signaling path-
ways are initiated by binding of IFN-α to the
heterodimeric interferon-α/β receptor, consecutively ac-
tivating JAK/STAT pathways. Phosphorylated STAT1
homodimers and/or the interferon-stimulated gene fac-
tor 3 (ISGF3) complex, comprising phosphorylated
STAT1, phosphorylated STAT2 and interferon regula-
tory factor 9 (IRF9), are formed, leading to the tran-
scriptional activation of interferon-stimulated genes
(ISGs) [17,18]. Classical well-characterized ISGs include
2’,5’-oligoadenylate synthetase (OAS), protein kinase R
(PKR), interferon regulatory factors (IRFs) and myxo-
virus resistance (Mx) genes [15,17,19]. Although the
precise function of several other ISGs remains poorly
understood, expression of ISGs inhibits replication of
various types of viruses [19-23]. In addition to antiviral
activity, IFN-α has profound effects on apoptosis and
immune response in several types of human cancer
and viral infections [16,24-31].
HIV-1 replication can be inhibited in vitro by IFN-α
in both macrophages as well as T cells, affecting bothearly and late stages of the viral replication cycle
[20,32-38]. Antiviral activity of IFN-α was characterized
by the expression of numerous ISGs. However, the
in vivo antiviral activity of IFN-α and its contribution
to HIV-1 disease progression remain controversial and
need to be further elucidated. Higher levels of serum
IFN-α, IFN-α-induced immune activation and higher
transcriptional levels of ISGs are paradoxically corre-
lated with higher HIV-1 viral load in HIV-1-infected
individuals [39-43], as well as disease progression,
questioning its antiviral activity in vivo. Nevertheless,
clinical trials have reported modest but significant
decreases in HIV-1 viral load after IFN-α treatment
[13,44-46].
In HTLV-1-infected cells, in vitro antiviral activity has
been reported for IFN-α by a post-transcriptional mech-
anism impairing viral assembly. Hereby, IFN-α had no
effect on viral protein synthesis, but inhibited virion re-
lease through the inhibition of Gag protein association
with lipid rafts [47]. In addition, IFN-α stimulation
induced transcriptional activation of ISGs in HTLV-1-
infected cells, reflecting intact IFN-α signaling pathways
[48]. However, HTLV-1 expression has been reported to
blunt IFN-α signaling pathways in vitro via HTLV-1 Tax
and suppressor of cytokine signaling 1 (SOCS1) expres-
sion [48-50]. Such inhibition could impair antiviral,
immunomodulatory and antiproliferative activities of
IFN-α in vivo. Nevertheless, significant clinical benefit
has been demonstrated for ATLL patients treated with
AZT and IFN-α combination therapy and HAM/TSP
patients treated with IFN-α monotherapy [7,51,52]. In
conclusion, although IFN-α signaling pathways contrib-
ute extensively to the host immune and antiviral
responses and therefore significantly determine the
therapeutic success of IFN-α treatment, controversy
exists in the exact mechanism of action of IFN-α in
retroviral infections.
In the present study, we address the possible antiviral,
antiproliferative and/or pro-apoptotic effects of IFN-α in
HTLV-1 mono-infected and HIV-1/HTLV-1 co-infected
CD4+ T cell lines in vitro. We demonstrate that IFN-α
exerts pronounced anti-HIV-1 effects in HTLV-1 co-
infected cells, but has a limited, post-transcriptional,
antiviral effect upon HTLV-1 in mono-infected cells. As
demonstrated by gene expression profiling, both STAT1/
STAT2-mediated antiviral signaling pathways and broad
ISGs induction were fully activated by IFN-α in HTLV-
1-infected cells. However, IFN-α failed to inhibit mRNA
levels of any of the known HTLV-1 genes or to induce
significant pro-apoptotic or antiproliferative activity in
HTLV-1-infected cells. In conclusion, the apparent ab-
sence of IFN-α antiretroviral activity is selective towards
HTLV-1, since a significant anti-HIV-1 effect can be
observed in co-infected cells.
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IFN-α selectively affects cell viability of HIV-1/HTLV-1 co-
infected but not HTLV-1 mono-infected cells
To assess the effects of IFN-α on cell viability of HTLV-
1-infected cell lines, we quantified pro-apoptotic (active-
caspase 3) and proliferation-associated (PCNA) markers
via flow cytometry after IFN-α treatment (10 - 103 IU/ml)
at different time points. As illustrated in Figure 1, IFN-α
had no marked effect upon active-caspase 3-positive
cells in three different HTLV-1-infected CD4+ T cell
lines (C8166, MT-2 and MT-4) at 24, 48 and 72 hours
of treatment. C8166 cells showed a spontaneous decline
in proliferation (Figure 1A), reflected by pronounced
time-dependent reduction in the percentage of PCNA-
positive cells, making them unsuitable for long-term
experiments (> 72 hours), which were further on car-
ried out only with MT-2 and MT-4 cells. We observed
a modest, but significant, decrease in the percentage of
PCNA-positive MT-4 cells by 18.7 ± 5.4% (n = 6, t-test,
p = 0.006), after 48 hours of treatment (Figure 1C–D).Figure 1 Flow cytometric analysis of cell death- and cell proliferation
CD4+ T cell lines, (A) C8166, (B) MT-2 and (C) MT-4 were treated for 24, 48
fixed concentration of 1000 IU/ml. The percentage of active-caspase 3-posi
(PCNA) were determined by flow cytometry and shown in the y-axis. The t
shown in the x-axis. (D) MT-4 cells were treated for 48 hours with no treatm
cytometric quantification of cells with DNA fragmentation (Hoechst 33342-
nuclear antigen-positive cells (PCNA) and Fas receptor-positive cells (FAS) a
the x-axis. Parametric t-tests were used with p-values indicated by asterisksQuantification of additional cell death-associated mar-
kers (DNA fragmentation, surface Fas) revealed no pro-
apoptotic activity of IFN-α in MT-4 cells after 48 hours
of treatment (Figure 1D). Nevertheless, both MT-2 and
MT-4 cells were resistant to IFN-α after 72 hours
(Figure 1B–C) and even in long-term culture (15 days,
data not shown), with similar cell viability in compari-
son to untreated cells.
Using an established MTT assay [53], we assessed the
effects of IFN-α on cell viability of HIV-1 IIIB/HTLV-1
co-infected MT-4 cells and HTLV-1 mono-infected MT-
4 cells (HIV-1 negative, HTLV-1 positive). After 5 days
of in vitro stimulation with varying concentrations of
IFN-α (10 - 104 IU/ml), inhibition of the HIV-1-induced
cytopathic effect (CPE) on MT-4 cells was measured and
inhibitory concentration (IC50) was calculated. IFN-α
strongly inhibited the HIV-1-induced CPE on the co-
infected MT-4 cells with a mean IC50 of ± 83.5 IU/ml
(n = 3, area under curve, p < 0.0001, 2519 ± 91.22 versus
7316 ± 115.2, Figure 2A). In contrast, cell viability of-associated markers of HTLV-1-infected cell lines. HTLV-1-infected
and 72 hours with no treatment (NT) or IFN-α, illustrated here for a
tive cells (CAS) and proliferating cell nuclear antigen-positive cells
ime points of treatment together with the treatment conditions are
ent (NT) or IFN-α (1000 IU/ml) in six independent experiments. Flow
positive cells), active-caspase 3-positive cells (CAS), proliferating cell
re shown in the y-axis, whereas the treatment conditions are shown in
(* < 0.05, ** < 0.01 and *** < 0.001).
Figure 2 Cell viability, HIV-1 p24 and HTLV-1 p19 levels of HTLV-1 co- and mono-infected cells. HIV-1 IIIB/HTLV-1 co-infected and HTLV-1
mono-infected MT-4 cells were cultured in the absence or presence of varying concentrations of IFN-α (0 - 104 IU/ml). (A) Cell viability was
determined after 5 days of culture, based on reduction of MTT and expressed in optical density (OD). In parallel, (B) HIV-1 p24 protein and (C)
HTLV-1 p19 protein concentrations (pg/ml), were determined in cell-free supernatant of HIV-1/HTLV-1 co-infected and HTLV-1 mono-infected
MT-4 cells, respectively, after 48 hours of culture. In addition, (D) HTLV-1 positive MT-2 cells were treated for 48 hours with no treatment (NT) or a
fixed concentration of 1000 IU/ml of IFN-α, followed by quantification of HTLV-1 p19 protein levels in cell-free supernatant. (E) HTLV-1 p19 protein
levels were also determined in cell-free supernatant of PBMCs of HAM/TSP (n = 5) and ATLL (n = 6) patients, after 48-72 hours of culture in the
absence or presence of IFN-α (1000 IU/ml). Parametric t-tests were used with p-values indicated by asterisks (* < 0.05, ** < 0.01 and *** < 0.001).
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IFN-α treatment as demonstrated by a mean cytotoxic
concentration (CC50) higher than 10
4 IU/ml (highest
concentration tested, n = 3, Figure 2A), supporting flow
cytometric observations in MT-4 cells.
IFN-α induces a 1000-fold greater reduction of HIV-1 p24
vs. HTLV-1 p19 protein levels
Although IFN-α strongly induced anti-HIV-1 activity in
MT-4 cells, we observed no “anti-HTLV-1” activity ofIFN-α in MT-4 cells based on cell viability data (MTT
reduction and flow cytometry). Since HIV-1 p24 and
HTLV-1 p19 levels are bona fide readouts of virion pro-
duction, we quantified these viral proteins in cell-free
supernatant of HIV-1 IIIB/HTLV-1 co-infected and
HTLV-1 mono-infected MT-4 cells, respectively, treated
with increasing concentrations of IFN-α for 48 hours
(n = 3). IFN-α dose-dependently reduced HIV-1 p24 levels
(ANOVA, p < 0.0001, Bonferroni post-test, p < 0.05, sig-
nificant from 0.64 IU/ml), with a mean IC50 of 1.2 IU/ml
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duction and/or secretion in HIV-1/HTLV-1 co-infected
MT-4 cells (Figure 2B). In parallel, IFN-α did not mark-
edly affect HTLV-1 p19 levels in cell-free supernatant of
HTLV-1 mono-infected MT-4 cells (ANOVA, p = 0.96),
even at high doses (Figure 2C). In addition, HTLV-1 p19
protein levels were also determined in cell-free super-
natant of the HTLV-1 positive and virion-producing MT-
2 cell line. To obtain maximum biological activity, MT-2
cells were treated for 48 hours with a fixed concentration
of 1000 IU/ml of IFN-α. IFN-α significantly reduced p19
levels in cell-free supernatant of MT-2 cells by 31% (n = 5,
t-test, p = 0.0045, Figure 2D), confirming the results of
Feng et al. [47]. Nevertheless, IFN-α was 1,000-fold more
active against HIV-1 than HTLV-1, when judged according
to the inhibition of Gag protein levels (p24 for HIV-1 and
p19 for HTLV-1). In HIV-1 IIIB/HTLV-1 co-infected MT-
4 cells, 1.2 IU/ml of IFN-α inhibited 50% of HIV-1 p24
levels, whereas 1000 IU/ml of IFN-α was not even suffi-
cient to inhibit 50% of HTLV-1 p19 levels in HTLV-1
mono-infected cells.
To evaluate the potential clinical relevance of this ob-
servation, we quantified HTLV-1 p19 levels in cell-free
supernatant of HAM/TSP (n = 5) and ATLL (n = 6)
PBMCs. IFN-α exerted no significant effect upon p19
levels of HAM/TSP PBMCs (t-test, p = 0.63), in agree-
ment to our recent demonstration of a lack of ex vivo
antiviral, pro-apoptotic and antiproliferative effects of
IFN-α in HAM/TSP patients [54]. However, IFN-α
significantly decreased p19 levels of ATLL PBMCs with
26% (t-test, p = 0.031) (Figure 2E). This modest reduc-
tion of p19 levels observed in ATLL PBMCs was highly
similar to the IFN-α-induced reduction observed in MT-2
cells (Figure 2D) and to recent findings in larger cohorts
of HTLV-1-infected individuals [55] as well as ATL
patients (Khouri et al., unpublished).
Gene expression profiling of IFN-α-treated HTLV-1-
infected cell lines
While HIV-1 replication was extremely sensitive to IFN-
α antiviral activity in HIV-1/HTLV-1 co-infected MT-4
cells, anti-HTLV-1 activity remains questionable since
we did not detect an effect of IFN-α on cell viability of
HTLV-1 mono-infected cells. However, we could meas-
ure a modest inhibitory effect of IFN-α on HTLV-1 p19
protein levels in MT-2 cells. To clarify whether IFN-α
signaling is blunted in HTLV-1-infected cell lines, pos-
sibly explaining the lack of IFN-α responsiveness, we
performed gene expression profiling of MT-2 and MT-4
cells after 6 hours of IFN-α stimulation. Agilent Whole
Humane Genome microarray analysis was performed in
two separate microarray experiments with duplicate
samples for both cell lines. Gene expression profiling of
MT-2 revealed 77 genes significantly regulated by IFN-α,of which 64 were up- and 13 down-regulated. Gene ex-
pression profiling of MT-4 revealed 284 genes signifi-
cantly regulated by IFN-α, of which 262 were up- and 22
down-regulated. The top 20 of the most significant up-
regulated genes are shown in Table 1 for MT-2 and
Table 2 for MT-4 cells, and included classical ISGs such
as Mx, OAS and IRFs genes. We found no common
down-regulated genes for MT-2 and MT-4, while 69%
(44/64) of up-regulated genes of MT-2 were also up-
regulated in MT-4 cells. Altogether, gene expression pro-
filing demonstrated significant activation of ISGs and
thus intact IFN-α signaling in HTLV-1-infected MT-2
and MT-4 cells.
Pathway analysis confirms intact IFN-α antiviral signaling
pathways in HTLV-1-infected cell lines
In order to characterize possible antiviral, pro-apoptotic
and/or antiproliferative pathways represented by the re-
spective IFN-α up- and down-regulated genes, which
were identified via microarray analysis described above,
Ingenuity Pathway Analysis (IPA) was performed for
both cell lines. Genes were sorted into molecular gene
networks and canonical pathways, of which significantly
overrepresented networks/pathways were identified. In
the case of MT-2, seven molecular networks were identi-
fied as significantly modulated by IFN-α treatment. The
principal network contained 25 genes, all up-regulated,
representing antimicrobial and inflammatory responses.
In the case of MT-4, 12 molecular networks could be
identified as significantly modulated by IFN-α treatment.
The principal network contained 26 genes, all up-regu-
lated, representing infection mechanism. The principal
IFN-α-modulated canonical pathway was identical for
both cell lines, i.e. interferon signaling (Figure 3), al-
though subtle differences were observed (IFN-γ, MX1,
up-regulated only in MT-2 and JAK2, SOCS1, IRF1,
TAP1, OAS1, up-regulated only in MT-4). Thus, IPA
illustrated IFN-α-induced modulation of molecular net-
works and pathways implicated in viral infection and/or
IFN signaling in both cell lines. Moreover, no apoptotic,
cell cycle-related or antiproliferative pathways were
identified, corroborating our flow cytometry findings
that IFN-α had no effect on cell viability of HTLV-1-
infected cell lines.
Lack of antiviral activity of IFN-α in HTLV-infected cell
lines
To assess the possible antiviral activity of IFN-α against
HTLV-1 and to validate cellular genes identified through
microarray analysis, nCounter analysis was performed
[56]. All known HTLV-1 viral genes, including the anti-
sense HBZ, and a selection of specific cellular genes, i.e.
STAT1, STAT2, STAT3 and CD69, an IFN-induced early
activation marker of T lymphocytes, were included for
Table 1 Overview of the 20 most significant up-regulated




MX1 NM_002462 myxovirus (influenza virus) resistance 1
(mouse)
DTX3L NM_138287 deltex 3-like (Drosophila)
IFIT5 NM_012420 interferon-induced protein with
tetratricopeptide repeats 5
TMEM140 NM_018295 transmembrane protein 140
BCL2L14 NM_030766 BCL2-like 14 (apoptosis facilitator)
EIF2AK2 NM_002759 eukaryotic translation initiation factor
2-alpha kinase 2
SP100 NM_001080391 SP100 nuclear antigen
EPSTI1 AL831953 epithelial stromal interaction 1 (breast)
RTP4 NM_022147 receptor (chemosensory) transporter
protein 4
RSAD2 NM_080657 radical S-adenosyl methionine domain
containing 2
IRF7 NM_004031 interferon regulatory factor 7
TRIM21 NM_003141 tripartite motif-containing 21
IFIH1 NM_022168 interferon induced with helicase C
domain 1
TRIM25 NM_005082 tripartite motif-containing 25
C19orf66 NM_018381 chromosome 19 open reading frame 66
PARP9 NM_031458 poly (ADP-ribose) polymerase family,
member 9
PML NM_033244 promyelocytic leukemia
OAS3 NM_006187 2'-5'-oligoadenylate synthetase 3, 100 kDa
IFI44 NM_006417 interferon-induced protein 44
XAF1 NM_017523 XIAP associated factor 1
GAN: Genbank Accession Number.
Table 2 Overview of the 20 most significant up-regulated




IFIT1 NM_001548 interferon-induced protein with
tetratricopeptide repeats 1
STAT1 NM_007315 signal transducer and activator of
transcription 1, 91 kDa
ADAR NM_001111 adenosine deaminase, RNA-specific
IFIT5 NM_012420 interferon-induced protein with
tetratricopeptide repeats 5
IRF1 NM_002198 interferon regulatory factor 1
APOL6 NM_030641 apolipoprotein L, 6
MX2 NM_002463 myxovirus (influenza virus) resistance 2
(mouse)
HAPLN3 NM_178232 hyaluronan and proteoglycan link protein 3
EIF2AK2 NM_002759 eukaryotic translation initiation factor
2-alpha kinase 2
BCL2L14 NM_030766 BCL2-like 14 (apoptosis facilitator)
LAP3 NM_015907 leucine aminopeptidase 3
IRF7 NM_004029 interferon regulatory factor 7
ZBTB32 NM_014383 zinc finger and BTB domain containing 32
SP100 NM_001080391 SP100 nuclear antigen
EPSTI1 NM_033255 epithelial stromal interaction 1 (breast)
TBX21 NM_013351 T-box 21
SAMD9L NM_152703 sterile alpha motif domain containing 9-like
IFI27 NM_005532 interferon, alpha-inducible protein 27
TAP1 NM_000593 transporter 1, ATP-binding cassette, sub-
family B (MDR/TAP)
TNFSF13B NM_006573 tumor necrosis factor (ligand) superfamily,
member 13b
GAN: Genbank Accession Number.
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quantified and normalized to a cellular housekeeping
gene (hypoxanthine phosphoribosyl-transferase 1). IFN-α
significantly increased mRNA levels of STAT1 and
STAT2 genes in MT-2 and MT-4 cells (n = 4, t-test,
p = 0.0024, p = 0.010 and p = 0.0023, p = 0.032, re-
spectively, Figure 4), confirming functional activation of
JAK/STAT pathways and IFN-α antiviral signaling. More-
over, mRNA levels of cellular STAT3 and CD69 genes
were also significantly increased in MT-4 cells, confirming
our microarray results (n = 4, t-test, p = 0.0041, p = 0.0018,
respectively, data not shown). As indicated by pathway
analysis (Figure 5A-B), IFN-α predominantly activated
STAT1 and STAT2 signaling and downstream genes,
representing main antiviral pathways, rather than
STAT3 signaling, representing inflammatory and car-
cinogenic pathways. HTLV-1 viral mRNA levels were ±
10-fold higher in MT-2 cells, in comparison to MT-4
cells, in agreement with the superior virion productionby MT-2 cells (Figure 2C-D). Surprisingly, after 6 hours,
IFN-α treatment had no effect on mRNA levels of any
of the HTLV-1 viral genes in both cell lines (n = 4, t-test,
Figure 6A-B). Due to the surprising absence of an anti-
viral effect at 6 hours, we also performed nCounter ana-
lysis after 2 and 48 hours of IFN-α treatment of MT-2
and MT-4 cells to verify whether “early” or “late” inhib-
ition of HTLV-1 viral gene transcription might occur.
At 2 hours, IFN-α again had no effect on viral gene
mRNA levels in both cell lines (n = 4, t-test, data not
shown). However, IFN-α significantly increased mRNA
levels of STAT1 and STAT2 genes in MT-4 cells after
2 hours (n = 4, t-test, p = 0.023 and p = 0.029, respect-
ively, Additional file 1), illustrating early activation of
JAK/STAT pathways and IFN-α signaling. At 48 hours,
IFN-α again failed to considerably down-regulate HTLV-1
viral gene transcription (Additional file 1) although IFN-α
signaling was sustained in both MT-2 and MT-4 cells,
demonstrated by increased STAT1 and STAT2 mRNA
Figure 3 The principal IFN-α-modulated canonical pathway in MT-4 cells. Ingenuity Pathway Analysis (IPA) was performed on genes
regulated by IFN-α treatment (6 h) in MT-2 (A) and MT-4 cells (B). The principal canonical pathway, interferon signalling, is graphically displayed
for MT-4 only (C). The red colour indicates up-regulation with the intensity indicating the degree of the gene transcription change. The log2
fold-change values and p-values are indicated below each molecule. Full lines represent direct interactions, while dashed lines indirect
interactions. Network shapes are represented in the legend.
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induced intact and sustained IFN-α signaling in HTLV-1-
infected cell lines, without any antiviral activity at the tran-
scriptional level, as all HTLV-1 viral mRNA levels were
unaffected after 2, 6 and 48 hours of IFN-α treatment.Discussion
IFN-α treatment exerted a strong in vitro anti-HIV-1
effect in HIV-1/HTLV-1 co-infected MT-4 cells, demon-
strated by the dose-dependent inhibition of the HIV-1-
induced CPE and p24 secreted levels upon HIV-1
Figure 4 Quantification of STAT1 and STAT2 mRNA levels of HTLV-1-infected cell lines. HTLV-1-infected CD4+ T cell lines (A) MT-2 and (B)
MT-4 were treated for 6 hours with no treatment (NT) or IFN-α (1000 IU/ml). mRNA levels (fM) of cellular STAT1 and STAT2 genes were assessed
via nCounter analysis and shown in the y-axis, whereas the treatment conditions are shown in the x-axis. Parametric t-tests were used with
p-values indicated by asterisks (* < 0.05, ** < 0.01 and *** < 0.001).
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viability of HTLV-1-infected cell lines C8166, MT-2 nor
MT-4. Furthermore, we demonstrate for the first time
that IFN-α treatment did not affect HTLV-1 viral mRNA
levels in MT-2 and MT-4 cells, demonstrated by nCoun-
ter analysis at various time points. Although these obser-
vations suggest the lack of biological activity of IFN-α
against HTLV-1, we were able to confirm the previously
described post-transcriptional inhibition of HTLV-1 p19
secretion by IFN-α [47], both in cell lines as well as in
ATL patient samples. However, in comparison to the
strong dose-dependent inhibition of HIV-1 p24 levels,
IFN-α only modestly reduced p19 levels in cell-free
supernatant of MT-2 cells and ATL PBMCs. Despite the
absence of pronounced antiviral, pro-apoptotic and anti-
proliferative activity of IFN-α, microarray and nCounter
analysis revealed significant transcriptional activation of
ISGs and intact IFN-α signaling in MT-2 and MT-4
cells. MT-4 cells appeared to be more responsive to
IFN-α treatment in comparison to MT-2 cells, demon-
strated by significant up- or down-regulation of 284 vs.
77 genes, respectively, and the early activation of STAT1
and STAT2 genes. Nevertheless, approximately 70% of
the IFN-α-up-regulated genes in MT-2 were identical of
those up-regulated in MT-4 cells, indicating the similar-
ity and reliability of both cell lines as HTLV-1 in vitro
models.
Because of the intact transcriptional activation of ISGs,
the absence of distinct antiviral activity of IFN-α against
HTLV-1 was not due to a general defect in IFN-α signal-
ing pathways in MT-2 or MT-4 cells. In agreement with
our findings, over-expression of a subset of ISGs in
chronic HTLV-1 infection has recently been shown to
fail to constitute an efficient antiviral host response, butmight instead contribute to HAM/TSP pathogenesis
[55]. We speculate that IFN-α fails to decrease HTLV-1
mRNA levels due to highly virus-specific retroviral re-
striction factors, as IFN-α exerted strong anti-HIV-1 yet
weak anti-HTLV-1 effects in HIV-1/HTLV-1 co-infected
MT-4 cells. Since all known HTLV-1 mRNAs, including
antisense HBZ, remain unchanged upon IFN treatment,
defective RNAseL activity, downstream of OAS gene ac-
tivation (reviewed in [57]), might be hypothesized as a
possible HTLV-1 escape mechanism,. Although several
OAS family members are IFN-inducible in both HTLV-1
infection (this study, Table I and results not shown) and
HIV-1 infection [40], little is known of downstream
RNAse L activation, which occurs at the protein level
[57]. In addition, blunting of IFN-α biological activity has
been mainly addressed in HTLV-1 mono-infection, but
not in HIV-1/HTLV-1 coinfection. HTLV-1 expression
has been reported to up-regulate SOCS1 expression,
inducing ubiquitination and proteasomal degradation
of IRF3, leading to the inhibition of type I interferon
production and thus inhibiting activation of IFN-α sig-
naling pathways [50]. Still, up-regulation of SOCS1
mRNA levels was shown in CD4+ T cells isolated from
HAM/TSP patients and asymptomatic carriers, but not
from ATLL patients [50]. Furthermore, HTLV-1 Tax
has been shown to induce SOCS1 expression, leading
to the inhibition of RIG-I-dependent antiviral signaling,
but not the JAK/STAT signaling pathways [58]. Inhib-
ition of cytoplasmatic pattern recognition receptors
such as RIG-I, has been associated with IRF3 inhibition
and thus subsequent inhibition of type I interferon pro-
duction. Consequently, HTLV-1-induced SOCS1 ex-
pression could counteract activation of IFN-α signaling
via reduced type I interferon production. However,
Figure 5 (See legend on next page.)
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Figure 5 STAT1/STAT2 signaling pathways predominate following IFN-α treatment in MT-2 and MT-4 cells. Ingenuity Pathway Analysis
(IPA) was performed on genes regulated by IFN-α treatment (6 h) in MT-2 (A) and MT-4 cells (B). The red colour indicates up-regulation with the
intensity indicating the degree of the gene transcription change. The log2 fold-change values and p-values are indicated below each molecule.
Full lines represent direct interactions, while dashed lines indirect interactions. Network shapes are as in Figure 3.
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SOCS1 expression in HeLa-cells, HTLV-1 expressed
from an infectious molecular clone reduced IFN-α-
induced up-regulation of SOCS1 mRNA levels [48].
Taken together, the precise correlation between HTLV-
1 and SOCS1 expression and its effect on IFN-α signal-
ing, remains unclear. Our microarray analysis revealed
significant IFN-α-induced up-regulation of suppressors
of cytokine signaling SOCS1, SOCS2 and SOCS3 levels
in MT-4 cells, but not in MT-2 cells, although IPA
pathway analysis revealed strikingly similar IFN signal-
ing in both cell lines. Therefore, an IFN-α-induced
increased SOCS1 level is not a generalized finding in
HTLV-1 infection in vitro and is not by itself sufficient
to define the blunted biological activity of IFN-α.
HTLV-1 expression has also been reported to up-
regulate IRF4 levels in HTLV-1-transformed cell lines
and PBMCs of ATLL patients [59,60]. IRF4 was shown
to negatively regulate type I interferon production and
appeared to be associated with AZT + IFN-α antiviral
resistance in ATLL patients [59-61]. Our microarray
results showed no effect of IFN-α on IRF4 expression
in MT-2 or MT-4 cells, although more sensitive
nCounter analysis revealed slight IFN-α-induced up-
regulation of IFR4 levels, which was significant in MT-
4 cells, but not in MT-2 cells (p = 0.049 and p = 0.65,
respectively, data not shown). Furthermore, treatment
with exogenous IFN-α was able to activate IFN-α
signalling to a similar extent in both cell lines
(Figure 6A-B and Tables 1–2), although SOCS1 and
IRF4 were significantly up-regulated in MT-4 cells only.
Nevertheless, our study was limited to the broad antiviral,
pro-apoptotic and antiproliferative activities of IFN-α, as
well as IFN-α signaling in HTLV-1-infected cells, whereas
the precise contribution of cellular factors such as SOCS1
or IRF4 has been investigated in detail in previous studies
[50,58-61]. However, it should be stated that some of
these studies [48,50] investigate de novo infection with
HTLV-1 molecular clones, in contrast to stable HTLV-1
infection (this study). The latter might be closer to the
in vivo situation, considering the latency of the virus
in vivo and its slow molecular evolution, pointing at
limited de novo infection [1]. In addition, there is in-
creasing evidence that activation of multiple IFN-α sig-
naling pathways is required to generate the antiviral,
pro-apoptotic and immunomodulatory effects of IFN-α
[16]. Antiviral and antiproliferative activities of IFN-αhave been reported to depend on both STAT- and p38-
signaling pathways [62]. Although we observed tran-
scriptional activation of STAT1, STAT2 and downstream
ISGs in both MT-2 and MT-4 cells, other important
IFN-α signaling pathways, such as p38-signaling, could
be affected by HTLV-1 replication, possibly explaining
the absence of explicit antiviral or antiproliferative ac-
tivity against HTLV-1 in vitro.
Altogether, one can assume that the in vitro antiretro-
viral activity and, possibly, the in vivo therapeutic suc-
cess of IFN-α for both HIV-1 and HTLV-1 is determined
by virus-specific factors including viral life cycle-related
factors (replication, virion production) and the balance
between factors blunting or stimulating IFN-α signaling
pathways. For example, inhibition of HIV-1 assembly
and release of virions by IFN-α has been described
through the induction of ISG15, an ubiquitin-like pro-
tein [34]. Through ISG15 up-regulation, IFN-α could
affect HTLV-1 assembly, which could explain the post-
transcriptional inhibition of p19 secretion. On the other
hand, a recent systematic screen for antiviral activity of
389 ISGs, revealed the ability of ADAR to enhance HIV-
1 replication [31]. Unfortunately, no data are available
on IFN signaling and/or specific ISGs levels in HIV-1/
HTLV-1 co-infection, which is of significant clinical im-
portance since several cohort studies have revealed
accelerated clinical progression to AIDS and/or
increased mortality in HIV-1/HTLV-1 co-infected versus
HIV-1 mono-infected individuals [63-65].Conclusion
We found that IFN-α treatment of retrovirus-infected
CD4+ T cells revealed strong anti-HIV-1 but limited
anti-HTLV-1 effects. We demonstrate intact early as well
as sustained IFN-α signaling in HTLV-1-infected cells,
despite various reports of SOCS1- and HTLV-1 Tax-
induced blunting of IFN-α signaling. We speculate that
qualitative rather than quantitative differences in IFN-α
signaling and downstream ISGs could determine the
therapeutic success of IFN-α in vivo, depending on both
host genetics and disease context. Therefore, large
cohorts with long-term clinical follow-up of ATLL and
HAM/TSP patients, as well as HIV-1/HTLV-1 co-
infected individuals are required to identify viral and
host factors specifically limiting antiretroviral activity of
IFN-α against HTLV-1.
α α α α α α α α α α
α α α α α α α α α α
A
B
Figure 6 Quantification of HTLV-1 viral mRNA levels after 6 hours of IFN-α treatment. HTLV-1-infected CD4+ T cell lines (A) MT-2 and (B)
MT-4 were treated for 6 hours with no treatment (NT) or IFN-α (1000 IU/ml). mRNA levels (fM) of all known HTLV-1 viral genes were assessed via
nCounter analysis and shown in the y-axis, whereas the treatment conditions are shown in the x-axis, represented for each of the viral genes. No
statistical significance was observed for any gene (t-test).
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Reagents
IFN-α2A (3x106 IU/ml, a gift of Blausiegel Farmacêutica,
São Paulo, Brazil) stock solutions were prepared in
normal saline and working solutions in RPMI 1640
medium, supplemented with 10% heat inactivated
foetal calf serum, 20 μg/ml gentamicin and 75 mM
NaHCO3 (GIBCO
W Invitrogen, Belgium). Antiviral ac-
tivity of IFN-α was confirmed in a Vesicular Stomatitis
Virus/WISH bioassay [66].
Patients samples and cell lines
Diagnosis of HTLV-1 infection, HAM/TSP and ATLL
was made according to published criteria [67], combin-
ing ELISA (Murex), Western blot, INNO-LIA (Innoge-
netics) and clinical data. Written informed consent was
obtained from all participants and this study was
approved by the Ethics Committees of CpqGM-
FIOCRUZ and HUPES/UFBA (Salvador-Bahia, Brazil)
and the Universidad Peruana Cayetano Heredia (Lima,Peru). PBMCs of 5 HAM/TSP and 6 ATLL patients (4
acute, 2 chronic) were isolated by Ficoll-Hypaque dens-
ity gradient centrifugation (Sigma-Aldrich).
PBMCs and chronically HTLV-1-infected cell lines,
C8166, MT-2 and MT-4 [68-70], were cultured in sup-
plemented RPMI 1640 medium. C8166 cells were
obtained from the Medical Research Council, UK),
MT-2 and MT-4 cells were from Harada et al. [71]. For
varying time spans, PBMCs (2 x 106 cells/ml) and
HTLV-1-infected cell lines (2 x 105 cells/ml) were trea-
ted in the absence or presence of IFN-α (10 - 104 IU/ml)
followed by flow cytometric analysis of HTLV-1-infected
cell lines. Given that MT-4 cells are highly susceptible to
HIV-1 infection and have been successfully used as a
drug screening model for the detection of anti-HIV com-
pounds [53], MT-4 cells (6 x 105 cells/ml) were infected
with HIV-1 IIIB strain [72] and cultured for 5 days in the
absence or presence of varying concentrations of IFN-α
(0.01 - 104 IU/ml). Hereby, antiviral activity of IFN-α
was measured via the 3-(4,5-dimethylthiazol-2-yl)-2,5-
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ing assay [53,73]. In parallel, HTLV-1-mono-infected
MT-4 cells (6 x 105 cells/ml) were cultured for 5 days in
the absence or presence of varying concentrations of IFN-α
(10 - 104 IU/ml). Cell viability was quantified by both
MTT assay and trypan blue dye exclusion protocols.
Flow cytometry assay
At different time points after IFN-α treatment, cell
lines were collected and DNA content (Hoechst
33342), cell death-associated (active-caspase-3, surface
Fas) and cell proliferation-associated (PCNA) markers
were quantified by flow cytometry (BD Biosciences).
Briefly, cells were fixed in Cytofix buffer (BD Bios-
ciences) for 10 minutes at 37°C. Cell pellets were per-
meabilized in 100% ice-cold methanol for 30 minutes.
Cells were then washed twice in 1x PBA (phosphate-
buffered saline + bovine serum albumin + NaN3) and
incubated with fluorescence-labelled monoclonal anti-
bodies at room temperature (APC mouse IgG1, FITC
mouse IgG2a, PE mouse IgG2a, APC anti-Fas, FITC
anti-PCNA, PE anti-active Caspase-3). After 30 minutes,
cells were washed twice in 1 x PBA and stained with
Hoechst 33342. Cell populations and debris were defined
based on morphology via forward- versus side-scatter plots
and 10.000-100.000 events were acquired per sample.
HIV-1 p24 and HTLV-1 p19 quantification
HIV-1 capsid protein p24 and HTLV-1 matrix protein
p19 were quantified in cell-free supernatant of MT-4
and MT-2 cells, using HIV-1 p24 Core Profile ELISA kit
(PerkinElmer) and RetroTek HTLV-I/II p19 Antigen
ELISA kit (ZeptoMetrix), respectively. After 48–72 hours
of IFN-α treatment (1000 IU/ml), HTLV-1 p19 levels
were quantified in cell-free supernatant of HAM/TSP
and ATLL PBMCs.
Microarray analysis
Total RNA was extracted from MT-2 and MT-4 cells
treated in the absence or presence of IFN-α (1000 IU/
ml) at 6 hours, using RNeasy kit according to the manu-
facturer’s protocol (QIAgen Benelux B.V., Venlo, the
Netherlands). Agilent Whole Human Genome micro-
array analysis was performed by the VIB MicroArray
Facility (Leuven, Belgium). Data were analysed using
the Agilent Feature Extraction Software version 10.1.1.1
and 10.5.1.1. Briefly, the intensities of the fluorescent
probes Cy3 and Cy5, representing the transcription values,
were log2-transformed and normalized by quantile
normalization using the R package preprocessCore [74].
The contrasts in expression between IFN-α-treated and
untreated cells at 6 hours of stimulation were estimated
using the Limma package from Bioconductor (www.
bioconductor.org). For the selection of differentiallytranscribed genes, a fold-change cut-off of two (i.e. an
absolute log2-ratio larger than 1) was combined with a
p-value cut-off of p < 0.05 when corrected for multiple
testing. GEO submission of microarray data is detailed
in Additional file 2.
Ingenuity pathway analysis
The Ingenuity Pathway Analysis (IPA) program was used
to perform a pathway/function level analysis on genes
resulting from the microarray analysis for both MT-2
and MT-4 (IPA version 9.0, Build 116623, Content ver-
sion 3211, Ingenuity Systems, Red Wood City, CA).
Hereby, uncorrected p-values and absolute fold-changes
were used with cut-offs of p < 0.001 and fold-change
value of 2 (up or down), respectively. Based on a scien-
tific literature database, genes were sorted into gene net-
works and canonical pathways and significantly
overrepresented pathways were identified. The max-
imum number of networks to be generated was set to
25, with a maximum number of 35 molecules per net-
work. The signaling pathways and networks in Figure 3
were generated through the use of IPA (Ingenuity Sys-
tems, www.ingenuity.com).
nCounter analysis
Total RNA was extracted from MT-2 and MT-4 treated
in the absence and presence of IFN-α (1000 IU/ml) at 2,
6 and 48 hours, using RNeasy kit according to the man-
ufacturer’s protocol (QIAgen Benelux B.V., Venlo, the
Netherlands). nCounterTM (NanoString Technologies,
Seattle, United States) analysis was performed at the VIB
MicroArray Facility (Leuven, Belgium), based on direct
molecular bar-coding of target RNA transcripts and
digital detection [56]. Through the use of colour-coded
probe pairs, without the use of reverse transcriptase nor
amplification, mRNA transcripts of HTLV-1 viral genes
and specific cellular genes, including housekeeping genes
for normalization, were quantified in MT-2 and MT-4
cells after 2, 6 and 48 hours of IFN-α treatment (HTLV-1
Tax/Rex, Gag, protease, polymerase, gp46, gp21,
NC_001436.1; HTLV-1 p13, p12, p30, AB513134;
HTLV-1 HBZ, DQ273132; STAT1, NM_007315.2;
STAT2, NM_005419.2; STAT3, NM_139276.2; CD69,
NM_001781.1).
Statistical analysis
Statistical analysis was performed with GraphPad Prism
5 software. Parametric t-tests were used and p < 0.05 was
considered significant.
In microarray analysis, a moderated t-test was used, as
implemented in the Limma package, to test whether a
contrast was significantly different from zero. To verify
the false discovery rate, p-values were corrected for mul-
tiple testing with Benjamini-Hochberg.
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Additional file 1: Early and late effects of IFN-α on mRNA levels
of STAT and HTLV-1 genes. The HTLV-1-infected CD4+ T cell line MT-4
was treated for 2 and 48 hours with no treatment (NT) or IFN-α
(1000 IU/ml). mRNA levels of cellular and viral genes were assessed via
nCounter analysis. (A) STAT1 and STAT2 mRNA levels are represented for
MT-4 cells after 2 hours of treatment. mRNA levels of (B) HTLV-1 viral
genes and (C) STAT1 and STAT2 cellular genes are represented after
48 hours of treatment. mRNA levels (fM) are shown in the y-axis, whereas
the treatment conditions are shown in the x-axis. Parametric t-tests were
used with p-values indicated by asterisks (* < 0.05, ** < 0.01 and *** < 0.001).
Additional file 2: GEO submission microarray data.doc.
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